Navigation Links
Tests Might Diagnose, Predict Prostate Cancer

One measures genes in urine, another combines PSA and other risk factors

TUESDAY, Feb. 24 (HealthDay News) -- One study suggests that a simple urine test could pick out 50 percent of men with prostate cancer. Another study says that combining risk factors for prostate cancer may help predict the likelihood of developing the disease.

Both studies were presented Tuesday at the 2009 Genitourinary Cancers Symposium in Orlando, Fla., sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.

"Current methods for diagnosing prostate cancer -- PSA (prostate-specific antigen) and digital rectal exam -- have low specificity," lead researcher Jack Groskopf, a senior research scientist for Gen-Probe Inc., in San Diego, said during a Tuesday teleconference. "As a result, the majority of prostate biopsies are negative, and you could argue that we are doing too many biopsies."

There is a need for a better test and a better way to determine which men need aggressive treatment and which men need only monitoring, Groskopf said.

Toward these ends, Groskopf's team developed a urine test that can identify particular gene fusions associated with prostate cancer. The gene fusions involve the TMPRSS2 gene and the ERG gene. This particular fusion is found in about 50 percent of men with prostate cancer and can be identified in urine, Groskopf said.

"This is an ideal target for a diagnostic test," he said. "Another exciting aspect of the gene fusions is that they potentially provide an explanation for the progression of prostate cancer."

Using their test in 556 men before they underwent a biopsy, the researchers found the exam had a "specificity" for prostate cancer of 84 percent, compared with 27 percent for a PSA reading. The "sensitivity" of the test was 42 percent, but only half of men with the disease have this gene fusion, Groskopf noted.

The urine test also showed that it correlated well with other measures of gauging the aggressiveness of prostate cancer, Groskopf said.

In the second study, Dutch researchers used PSA readings, a family history of prostate cancer, the size of the prostate, and a previous negative biopsy to create a chart to predict the risk of developing prostate cancer.

The researchers tested their formula in 5,176 men who were screened for prostate cancer after four years. "PSA is still the most significant predictor, but there are other factors that also contribute risk," Monique J. Roobol, who's with the Department of Urology at the Erasmus Medical Center in Rotterdam, said during the teleconference.

The overall risk of developing prostate cancer was 5.1 percent, Roobol said. Men whose PSA levels were 1.5 nanograms per milliliter were seven times more likely to develop prostate cancer than men with a lower PSA, she said.

A family history of prostate cancer will increase the risk of the disease, as will having a small prostate, Roobol said. But if you have had a negative prostate biopsy, your risk decreases, she noted.

Men who have higher risk factors may need more frequent screening, Roobol said. "Men below this threshold may need less frequent screening," she added.

Dr. Durado Brooks, director of colon and prostate cancer prevention programs at the American Cancer Society, doesn't think either of these studies will change clinical practice anytime soon.

Discussing the first study, Brooks noted that this gene fusion is only found in half of prostate cancers. "If you don't find it, it doesn't mean prostate cancer isn't there," he said. "From a screening standpoint, this test is not likely to be very helpful at all."

As for the second study, Brooks said he wasn't sure that integrating these risk factors would effect patient treatment. "This is interesting, but I don't see how this is going to alter practice," he said.

A third study presented Tuesday looked at the benefit of using PET scans to diagnose bladder cancer. A research team led by Dr. Andrea B. Apolo, of Memorial Sloan-Kettering Cancer Center in New York City, compared PET scans with CT scans and MRIs to see which imaging technique was better at diagnosing the disease.

PET scans were more sensitive and specific in finding bladder cancer and distinguishing local from metastasized cancer, which is cancer that has spread to other sites in the body. In 68 percent of the cases studied, treatment plans were changed based on the results of the PET scans, the researchers said.

The researchers said these results argue for using PET scans as standard practice in diagnosing bladder cancer.

More information

For more on prostate and bladder cancer, visit the American Cancer Society.

SOURCES: Durado Brooks, M.D., director of colon and prostate cancer prevention programs, American Cancer Society, Atlanta; Feb. 24, 2009, teleconference with Jack Groskopf, Ph.D., senior research scientist for Gen-Probe Inc., San Diego; Monique J. Roobol, Ph.D., Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands; Andrea B. Apolo, M.D., Memorial Sloan-Kettering Cancer Center, New York City; presentations, 2009 Genitourinary Cancers Symposium sponsored by American Society of Clinical Oncology, American Society for Radiation Oncology, and the Society of Urologic Oncology, Orlando, Fla.

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Dauphin County Raw Milk Dairy Tests Negative for Listeria; Raw Milk Sales Resumed
2. PSA Tests Not Race-Specific, Study Finds
3. Six Questions Consumers Should Ask About Genetic Tests
4. Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable
5. OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections
6. Colorectal cancer: Immunological tests for more accurate detection of cancer precursors
7. Stool-Based Colon Cancer Tests Vary Widely in Accuracy
8. Agriculture Department Says Lancaster County Raw Milk Dairy Tests Positive for Salmonella
9. Study Weighs Cost, Benefit of Gene Tests Before Warfarin Rx
10. January 2009 Mayo Clinic Health Letter Highlights Improved PSA Tests, Dry Eyes and Colds
11. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... at the Radiological Society of North America (RSNA) 2015 conference. , Leading ... dictation and speech-enabled documentation software, announced their partnership today at RSNA 2015. ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, ... ... beauty are available today from the new company, Sublime Beauty NATURALS®. All products ... organic and natural products, like essential oils, organic facial serums and USDA Certified ...
(Date:11/29/2015)... ... ... The Cyber Monday deal is a deep 40% or more discount on every item on ... the skin care lover in your circle. Each Christmas, Sublime Beauty offers a special ... serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, natural ...
(Date:11/29/2015)... , ... November 29, 2015 , ... While conventional walkers ... or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has ... TOMMY WALKER to enhance the benefits of a standard walker to improve the user’s ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 27, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), ... biopharmaceuticals company UCB S.A. (Euronext: UCB). ... acquired KU from UCB for total consideration of ... a customary working capital adjustment, a deduction of ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology: